Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Glutamate and Parkinson's disease

F Blandini1, R H Porter, J T Greenamyre

  • 1Neurological Institute C. Mondino, University of Pavia, Italy.

Molecular Neurobiology
|February 1, 1996
PubMed
Summary

Glutamate excitotoxicity and impaired neuronal metabolism are key in Parkinson's disease (PD) pathology. Targeting the glutamatergic system offers potential therapeutic strategies for PD symptoms.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Combined assessment of blood glucocerebrosidase activity and α-synuclein levels in GBA1 mutation carriers: A novel potential biomarker.

Parkinsonism & related disorders·2025
Same author

LRRK2 G2019S-induced mitochondrial DNA damage is LRRK2 kinase dependent and inhibition restores mtDNA integrity in Parkinson's disease.

Human molecular genetics·2017
Same author

Effects of L-DOPA/benserazide co-treatment on colonic excitatory cholinergic motility and enteric inflammation following dopaminergic nigrostriatal neurodegeneration.

Neuropharmacology·2017
Same author

Response of colonic motility to dopaminergic stimulation is subverted in rats with nigrostriatal lesion: relevance to gastrointestinal dysfunctions in Parkinson's disease.

Neurogastroenterology and motility·2015
Same author

LC/MS analysis of cardiolipins in substantia nigra and plasma of rotenone-treated rats: Implication for mitochondrial dysfunction in Parkinson's disease.

Free radical research·2015
Same author

Mitochondrial DNA damage: molecular marker of vulnerable nigral neurons in Parkinson's disease.

Neurobiology of disease·2014

Area of Science:

  • Neuroscience
  • Neurodegenerative Disorders
  • Pathophysiology

Background:

  • Parkinson's disease (PD) involves altered glutamatergic neurotransmission and neuronal metabolic dysfunction.
  • The substantia nigra pars compacta is vulnerable to oxidative stress, metabolic insults, and excitotoxicity due to impaired mitochondrial function.
  • Glutamate may act as a neurotoxin when cellular energy metabolism is compromised, contributing to PD pathogenesis.

Purpose of the Study:

  • To investigate the role of glutamatergic neurotransmission in Parkinson's disease.
  • To explore the link between metabolic dysfunction and glutamate excitotoxicity in PD.
  • To identify potential therapeutic targets within the glutamatergic system for PD.

Main Methods:

  • Review of existing literature on PD pathophysiology.
  • Analysis of the role of glutamate in basal ganglia circuitry.
  • Examination of evidence from animal models of PD.

Main Results:

  • Altered glutamatergic neurotransmission is central to PD pathophysiology.
  • Impaired mitochondrial function increases vulnerability to glutamate excitotoxicity in nigral neurons.
  • Dopaminergic depletion in PD leads to overactive glutamatergic projections and altered receptor regulation.
  • Evidence suggests increased glutamatergic activity in the striatum of PD patients.
  • Blockade of glutamate receptors in animal models ameliorates PD motor symptoms.

Conclusions:

  • Abnormal glutamatergic neurotransmission patterns are significant in PD symptomatology.
  • The glutamatergic system represents a promising target for therapeutic interventions in Parkinson's disease.
  • Understanding glutamate's role provides new avenues for treating this neurodegenerative disorder.

Related Experiment Videos